• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » LivaNova starts limited European launch of perfusion system for cardiopulmonary bypass

LivaNova starts limited European launch of perfusion system for cardiopulmonary bypass

February 8, 2023 By Sean Whooley

https://www.massdevice.com/wp-content/uploads/2023/02/First_CPB_Essenz_-_External.mp4
LivaNova Essenz perfusion system for cardiopulmonary bypass
The Essenz perfusion system. [Image courtesy of LivaNova]
LivaNova (Nasdaq:LIVN) announced today that it began a limited commercial release for its Essenz perfusion system in Europe.

The company initiated its launch in select centers throughout Europe after successful implementation in The Netherlands and Italy.

London-based LivaNova built the Essenz system with a next-generation heart-lung machine and a patient monitor. The company designed it to deliver a patient-tailored approach that supports data-drive decisions during cardiopulmonary bypass procedures.

Catharina Hospital in Eindhoven, The Netherlands carried out the first clinical cases with Essenz. San Donato Hospital in Milan, Italy represented the other European center to kick off the launch. Eddy Overdevest, a perfusionist at Catharina Hospital, said Essenz creates “a new era” of personalized care.

“We are very satisfied with the way the machine is performing and excited to finally be able to use it to support patients during open-heart procedures,” said Mauro Cotza, chief perfusionist at San Donato Hospital. “We were pleased to be the first hospital in the world to place a patient on bypass with Essenz during a minimally invasive mitral valve replacement surgery.”

More about the LivaNova Essenz perfusion system

LivaNova worked with more than 300 perfusionists during the design and development process, the company said. It sought to create a system that provides flexibility and scalability to optimize intraoperative care coordination.

Essenz builds upon the LivaNova S5 HLM system, the company said. Its patient monitor and HLM cockpit connect but operate separately. Additionally, each pump on Essenz is controlled individually. The system features accurate sensing technology and an intuitive dashboard on the patient monitor.

It also includes an ergonomic design with advanced cable management and a mast-mounted design for hygiene purposes. The cockpit provides one central view to control the device, check all perfusion and monitor patient parameters.

Essenz also has backing from a responsive service team in more than 100 countries, LivaNova said.

“During open-heart procedures, perfusionists play a critical role and the perfusion system they use acts as the patient’s heart and lungs during the operation,” said Marco Dolci, president, cardiopulmonary at LivaNova. “Throughout the Essenz design process, we heard directly from perfusionists that they need a flexible and reliable system that gives them access to comprehensive data to inform their patient-tailored support in the OR.

“With the combination of next-generation hardware and software, the Essenz perfusion system will serve patients and empower perfusionists to make informed decisions as they provide increasingly tailored patient care.”

Filed Under: Business/Financial News, Cardiovascular, Patient Monitoring, Vascular Tagged With: LivaNova

More recent news

  • Former Shockwave Medical CEO joins Solenic Medical’s board
  • Anaconda Biomed brings in $56 million
  • Precision Neuroscience raises $250M in Series D for its BCI
  • Fresenius discontinuing Chinese sales of 4008A hemodialysis system
  • Perfuze’s super-bore stroke catheter tops conventional, cyclic aspiration in bench study

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

Cart

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy